Six-month concomitant and adjuvant hormonal treatment with external beam irradiation is inferior to 3-years hormonal treatment for locally advanced prostate cancer: Results of the eortc randomised phase III trial 22961

被引：7
|
作者：
Bolla, M. [1 ]
De Reijke, Th. M. [2 ]
Van Tienhoven, G. J. [3 ]
Van Den Bergh, A. C. M. [4 ]
Oddens, J. [5 ]
Poortmans, P. M. P. [6 ]
Gez, E. [7 ]
Kil, P. J. M. [8 ]
Musat, E. [9 ]
Collette, L. [10 ]
机构：
[1] CHU Grenoble, Dept Radiotherapy, F-38043 Grenoble, France
[2] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Radiotherapy, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Groningen, Med Ctr, Dept Radiotherapy, Groningen, Netherlands
[5] Jeroen Bosch Hosp, Dept Urol, Shertogenbosch, Netherlands
[6] Dr Bernard Verbeeten Inst, Dept Radiotherapy, Tilburg, Netherlands
[7] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[8] St Elizabeth Hosp, Dept Urol, Tilburg, Netherlands
[9] Eortc Data Ctr, Dept Med Affairs, Brussels, Belgium
[10] Eortc Data Ctr, Dept Stat, Brussels, Belgium
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2008年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1569-9056(08)60185-2
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
186
引用
收藏
页码：117 / 117
页数：1
相关论文
共 40 条
  • [31] Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial
    Ito, Kazuto
    Kobayashi, Mikio
    Komiyama, Motokiyo
    Naito, Seiji
    Nishimura, Kazuo
    Yonese, Junji
    Hashine, Katsuyoshi
    Saito, Shiro
    Arai, Gaku
    Shinohara, Mitsuru
    Masumori, Naoya
    Shimizu, Nobuaki
    Satoh, Takefumi
    Yamauchi, Atsushi
    Tochigi, Tatsuo
    Takezawa, Yutaka
    Fujimoto, Hiroyuki
    Yokomizo, Akira
    Kakimoto, Ken-Ichi
    Fukui, Iwao
    Karasawa, Katsuyuki
    Tsukamoto, Taiji
    Nozaki, Miwako
    Hasumi, Masaru
    Ishiyama, Hiromichi
    Ohtani, Mikinobu
    Kuwahara, Masaaki
    Harada, Masaoki
    Ohashi, Yasuo
    Kotake, Toshihiko
    Kakizoe, Tadao
    Suzuki, Kazuhiro
    Yamanaka, Hidetoshi
    CANCER, 2020, 126 (17) : 3961 - 3971
  • [32] A feasibility study preparing to a phase III randomised trial comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. A trial conducted by the European Lung Cancer Working Party (ELCWP)
    Berghmans, T
    Sculier, J
    Recloux, P
    Van Cutsem, O
    Efremidis, A
    Holbrechts, S
    Roelandts, M
    Fraikin, J
    Ninane, V
    Van Houtte, P
    LUNG CANCER, 2005, 49 : S166 - S166
  • [33] Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study
    Therasse, P
    Mauriac, L
    Welnicka-Jaskiewicz, M
    Bruning, P
    Cufer, T
    Bonnefoi, H
    Tomiak, E
    Pritchard, KI
    Hamilton, A
    Piccart, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 843 - 850
  • [34] Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial
    Fransson, Per
    Lund, Jo-Asmund
    Damber, Jan-Erik
    Klepp, Olbjorn
    Wiklund, Fredrik
    Fossa, Sophie
    Widmark, Anders
    LANCET ONCOLOGY, 2009, 10 (04): : 370 - 380
  • [35] Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
    Eggermont, Alexander M. M.
    Chiarion-Sileni, Vanna
    Grob, Jean-Jacques
    Dummer, Reinhard
    Wolchok, Jedd D.
    Schmidt, Henrik
    Hamid, Omid
    Robert, Caroline
    Ascierto, Paolo Antonio
    Richards, Jon M.
    Lebbe, Celeste
    Ferraresi, Virginia
    Smylie, Michael
    Weber, Jeffrey S.
    Maio, Michele
    Hosein, Fareeda
    de Pril, Veerle
    Kicinski, Michal
    Suciu, Stefan
    Testori, Alessandro
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : 1 - 10
  • [36] Chemoradiation (CRT) followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant CRT and surgery for locally advanced rectal cancer: Results of the Spanish GCR-3 randomized phase II trial after a median follow-up of 5 years.
    Fernandez-Martos, Carlos
    Pericay, Carles
    Aparicio, Jorge
    Jose Safont, Maria
    Salud, Antonia
    Massuti, Bartomeu
    Alonso, Vicente
    Vera, Ruth
    Escudero, Pilar
    Martin-Richard, Marta
    Bosch, Carlos
    Maurel, Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [37] Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Schmid, Peter
    Rugo, Hope S.
    Adams, Sylvia
    Schneeweiss, Andreas
    Barrios, Carlos H.
    Iwata, Hiroji
    Dieras, Veronique
    Henschel, Volkmar
    Molinero, Luciana
    Chui, Stephen Y.
    Maiya, Vidya
    Husain, Amreen
    Winer, Eric P.
    Loi, Sherene
    Emens, Leisha A.
    LANCET ONCOLOGY, 2020, 21 (01): : 44 - 59
  • [38] Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Rolski, J.
    Grodzki, T.
    Schneider, C. P.
    Zatloukal, P.
    Reck, M.
    Aitin, E.
    Tan, E. H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 356 - 356
  • [39] Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer
    Tan, E. H.
    Rolski, J.
    Grodzki, T.
    Schneider, C. P.
    Gatzemeier, U.
    Zatloukal, P.
    Aitini, E.
    Carteni, G.
    Riska, H.
    Tsai, Y. H.
    Abratt, R.
    ANNALS OF ONCOLOGY, 2009, 20 (07) : 1249 - 1256
  • [40] Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)
    Tan, Eng-Huat
    Grodzki, Tomasz
    Schneider, Claus-Peter
    Zatloukal, Peter
    Reck, Martin
    Aitini, Enrico
    Rolski, Janusz
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S451 - S451
1234